Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aveo Pharmaceuticals, Inc.

      Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aveo
                            Pharmaceuticals, Inc.

PR Newswire

NEW YORK, May 3, 2013

NEW YORK, May 3, 2013 /PRNewswire/ --Attorney Advertising -- Bronstein,
Gewirtz & Grossman, LLC is investigating potential claims on behalf of
purchasers of the securities of Aveo Pharmaceuticals, Inc. ("Aveo" or the
"Company") (NasdaqGS: Aveo). The investigation focuses on whether the Company
and its executives violated federal securities laws.

On May 2, 2013, shares of Aveo Pharmaceuticals plunged almost 50 percent after
the company said a Food and Drug Administration ("FDA") panel recommended its
drug Tivopath not be approved as a treatment for advanced kidney cancer. The
FDA advisory panel rejected approval for AVEO's drug tivozanib by a vote of
13-1; Aveo hadn't demonstrated the medicine's benefits outweigh the risks.

If you are aware of any facts relating to this investigation, or purchased
shares of Aveo, you can assist this investigation by contacting Peretz
Bronstein of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email
info@bgandg.com. Those who inquire by e-mail are encouraged to include their
mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our
primary expertise is the aggressive pursuit of litigation claims on behalf of
our clients. In addition to representing institutions and other investor
plaintiffs in class action security litigation, the firm's expertise includes
general corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not guarantee similar
outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein 212-697-6484
info@bgandg.com

SOURCE Bronstein, Gewirtz & Grossman, LLC